American hospitals face relentless financial pressure, squeezed between rising costs and complex reimbursement. Craneware (LSE:CRW), a Scottish-headquartered but US-focused software company, has built a Business helping them manage exactly these problems. The intriguing dynamic is that the harder hospitals’ finances become, the greater the Demand for software that helps them get paid correctly and control costs.
Software for hospital finances
Craneware provides financial and operational software to US healthcare providers through its Trisus platform, helping them with pricing, charge capture, cost analysis and regulatory compliance. Its products aim to ensure hospitals capture the Revenue they are entitled to and understand their true costs, in a system famous for its complexity. Although listed on London’s AIM, essentially all of its business is in the United States, giving it exposure to the world’s largest healthcare market.
The 2025 numbers
For the year to 30 June 2025, Craneware reported revenue of about US$205.7 million, up 9%, with adjusted EBITDA rising 12% to roughly US$65.3 million at a Margin near 32%. Annual Recurring Revenue was around US$184 million, net revenue retention improved to about 107%, and statutory pre-tax profit jumped about 52% to some US$24 million. The company held cash of about US$55.9 million, reduced its bank debt, and raised its total Dividend 10% to 32 pence per share.
Why pressure drives demand
The logic of the business is counter-cyclical in an appealing way. When hospitals are under financial strain, tools that help them recover revenue, reduce leakage and manage costs become more valuable, not less. High net revenue retention above 100% shows existing customers are spending more over time, a sign the software becomes embedded in daily operations. Recurring revenue and strong retention give Craneware a predictable base, while its Investment in artificial intelligence within Trisus aims to deepen that value further.
The value of recurring revenue
The heart of Craneware’s quality lies in the recurring nature of its income. Hospitals typically sign multi-year contracts for its software, and because the tools become woven into daily financial workflows, they are rarely dropped once installed. This produces a large base of predictable annual recurring revenue and high customer retention, which together make future income easier to forecast than for a business reliant on one-off sales. Net revenue retention above 100% means the average customer spends more each year, whether by adopting new modules or expanding usage, so growth can come from the existing base as well as new wins. For investors, this recurring, sticky revenue is what gives a software company its resilience, cushioning it against short-term swings and supporting steady investment in the platform and its emerging AI capabilities.
The risks to weigh
Craneware’s reliance on the US healthcare system is both its strength and its risk. Changes to American healthcare policy, reimbursement rules or hospital funding could affect customers’ budgets and priorities. Sales cycles to large health systems can be long, and competition from other health-technology providers is real. As a sterling-reporting company earning in dollars, it is exposed to currency movements. Sustaining growth also depends on continually enhancing its platform and persuading customers to adopt new modules.
So how could pressure become demand?
Craneware (LSE:CRW) could turn hospital hardship into growth by positioning its software as essential to financial survival, expanding recurring revenue as providers adopt more of its tools and its AI features. The 2025 results, with rising recurring revenue and improving retention, suggest the model is working. Risks around US policy and competition remain, and growth is steady rather than explosive. But if hospitals keep needing help to protect their finances, Craneware’s software demand should prove resilient, turning pressure into opportunity.






Please wait processing your request...